PSNL News and Press, Personalis Inc. From 01/06/22

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021. Personalis estimates revenue of approximately $20.7 million for the fourth ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 24 th Annual Needham Virtual Growth Conference on Tuesday, January 11, 2022. About Personalis Personalis, Inc. is a leader in advanced c...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Personal, a next-generation, tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease (MRD) and recurrence in patients previously diagnosed ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 33 rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1, 2021. Interested parties may access the pre-recorded and arch...

Personalis recognized in inaugural roundup for proven track record of management excellence Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has been named to Inc. ’s inaugural 2021 Best-Led Companies list ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 12-14, including online poster presentations and online industry sponsored symposium. ...

Personalis, Inc. (PSNL) Q3 2021 Earnings Conference Call November 4, 2021 8:30 AM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Neel Ram...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the third quarter ended September 30, 2021. Third Quarter and Recent Highlights Reported quarterly revenue of $22.3 million in the thir...

Personalis (NASDAQ:PSNL) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.42 and the consensus Revenue Estimate is $22.24M (+12.3% Y/Y). Over the last 3 months, EPS estimates have seen 6 upward revisions and 2 downwa...

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...